This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Jimena, P Articles by Cuadrado, M J Search for Related Content PubMed PubMed Citation Articles by Jimena, P Articles by Cuadrado, M J Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Lupus Social Bookmarking                         What's this?

Prolactin levels in patients with systemic lupus erythematosus: a case controlled study

Departments of Rheumatology, University Hospital ‘Reína Sofá’, Córdoba, Spain

M A Aguirre

Departments of Rheumatology, University Hospital ‘Reína Sofá’, Córdoba, Spain

A López-Curbelo

M de Andrés

Departments of Rheumatology, University Hospital ‘Reína Sofá’, Córdoba, Spain

C Garcia-Courtay

M J Cuadrado

Departments of Rheumatology, University Hospital ‘Reína Sofá’, Córdoba, Spain

Recent accumulated evidence suggests that prolactin (PRL) is an important immunomodulator and might have a role in the pathogenesis of systemic lupus erythematosus (SLE). Our aim was to assess the frequency of hyperprolactinemia in women with SLE and to evaluate its correlation with disease activity. PRL plasma levels were measured in 36 women with SLE and 20 age-matched healthy controls. We excluded patients with renal and/or hepatic failure, pregnant patients and patients taking drugs which could increase PRL levels. Disease activity was assessed using the SLE disease activity index (SLEDAI). Patients with a score > 10 were considered active. In patients and controls, PRL levels were determined by radioimmunoassay (RIA) during the first part of the menstrual cycle (between the 5th and 8th day) (normal value < 20 ng/ml). Ten of 36 (27.7%) SLE patients had high PRL levels (> 20 ng/ml). The mean PRL level was higher in SLE than in the control group (17.1=12.9 s.d. vs 9.= 3.5, P < 0.01). Patients with active disease had a trend to higher mean PRL levels than inactive patients although this difference was not statistically significant (21.1=4.8 vs 14.8= 6.9, P = 0.09). No correlation was found between PRL levels and SLEDAI score. Furthermore, no significant correlation was found between PRL levels and any clinical or serological finding.

Key Words: endocrinology • immunomodulation • hormones

Lupus, Vol. 7, No. 6, 383-386 (1998)
DOI: 10.1191/096120398678920361


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Raptopoulou, P. Sidiropoulos, and D. T Boumpas Ovarian failure and strategies for fertility preservation in patients with systemic lupus erythematosus Lupus, December 1, 2004; 13(12): 887 - 890. [PDF]

				M Garcia, M E Colombani-Vidal, C C Zylbersztein, A Testi, J Marcos, A Arturi, J Babini, and H E Scaglia Analysis of molecular heterogeneity of prolactin in human systemic lupus erythematosus Lupus, August 1, 2004; 13(8): 575 - 583. [Abstract] [PDF]

				A Hrycek, D Kokocinska, J Kosmider, and B Konieczny Letter to the Editor Lupus, February 1, 2003; 12(2): 149 - 152. [PDF]

				S G Pasoto, B B Mendonca, and E Bonfa Menstrual disturbances in patients with systemic lupus erythematosus without alkylating therapy: clinical, hormonal and therapeutic associations Lupus, March 1, 2002; 11(3): 175 - 180. [Abstract] [PDF]

				S E Walker and L.-y. Yu-Lee Overview: prolactin and autoimmunity Lupus, October 1, 2001; 10(10): 659 - 659. [PDF]

				L J Jara, O Vera-Lastra, J M Miranda, M Alcala, and J Alvarez-Nemegyci Prolactin in human systemic lupus erythematosus Lupus, October 1, 2001; 10(10): 748 - 756. [Abstract] [PDF]

				A M Jacobi, W Rohde, M Ventz, G Riemekasten, G-R Burmester, and F Hiepe Enhanced serum prolactin (PRL) in patients with systemic lupus erythematosus: PRL levels are related to the disease activity Lupus, August 1, 2001; 10(8): 554 - 561. [Abstract] [PDF]

				A Hrycek, P Cieslik, J Tustanowski, S Nowak, and P Jedynak Selected serum cytokines in systemic lupus erythematosus treated with quinagolide Lupus, June 1, 2001; 10(6): 424 - 430. [Abstract] [PDF]

				S E Walker Treatment of systemic lupus erythematosus with bromocriptine Lupus, March 1, 2001; 10(3): 197 - 202. [Abstract] [PDF]

				A M Jacobi, W Rohde, H-D Volk, T Dorner, G-R Burmester, and F Hiepe Prolactin enhances the in vitro production of IgG in peripheral blood mononuclear cells from patients with systemic lupus erythematosus but not from healthy controls Ann Rheum Dis, March 1, 2001; 60(3): 242 - 247. [Abstract] [Full Text] [PDF]

				S E Walker, D Miller, D L Hill, and G R Komatireddy Prolactin, a pituitary hormone that modifies immune responses: Proceedings of the Mini-symposium on Prolactin and SLE, held at the 5th International Conference on Systemic Lupus Erythematosus, Cancun, Mexico Lupus, July 1, 1998; 7(6): 371 - 375. [PDF]